1[1]Sevin BU, Peng ZL, Perras JP, et al. Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing [J]. Gynecol Oncol, 1988,31: 191 -204.
2[2]Nguyen HN, Sevin BU, Averette HE, et al. Comparative evaluation of single and combination chemotherapy in uterine cancer cell lines[J]. Gyneco Oncol, 1991, 42:227 -232.
3[3]Ten Bokkel Huinink, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer [J]. J Clin Oncol, 1997, 15(6): 2183 -2193.
4[4]Gore M, ten Bokkel Huinink W, Carmichael J, et al. Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovarian cancer [J]. J Clin Oncol, 2001,19(7): 1893 - 1900.
5[5]Sauer R, Heuser A. Topoisomerase I inhibitor with potential radiosensitizing effect [J]. Strahlenther Onkol, 1997, 173(3):125 - 130.
6Bookman MA,McGuire WP Ⅲ ,Kilpatrick D,et al.Carboplatin and paclitaxel in ovarian carcinoma: a phase Ⅰ study of the Gynecologic Oncology Group [J].J Clin Oncol,1996,14:1895- 1902.
7McGuire WP,Hoskins WJ,Brady MF,et al.Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage Ⅲ and stage Ⅳ ovarian cancer [J].N Engl J Med,1996,334:1- 6.
8Ten Bokkel Huinink W,Gore M,Carmichael J,et al.Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer [J].J Clin Oncol,1997,15:2183- 2193.
9Eisenhauer EA,ten Bokkel Huinink WW,Swenerton KD,et al.European Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High dose versus low dose and long versus short infusion [J].J Clin Oncol,1994,12:2654- 2666.
10Burris H,Kuhn J,Johnson R,et al.SKF 104864.Preclinical studies of a new topoisomerase Ⅰ inhibitor [J].Proc Am Assoc Cancer Res,1990,31:431(abstr).
